Compare Adaptive Biotechnologies Corp (ADPT) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs VanEck Rare Earth/Strategic Metals — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while VanEck Rare Earth/Strategic Metals trades at $78.97. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| ADPT | REMX | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $109.53 |
52-Week Low | $10.24 | $41.94 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
REMX trades at $85.34, down 1.59% today, with a bearish technical signal driven by moving averages. The ETF is positioned in the rare earth and strategic metals sector, benefiting from geopolitical tensions and supply chain shifts. Recent news highlights strong institutional interest in materials and commodities, with REMX recognized for AI infrastructure and defense exposure. Key support is at $84, with resistance at $86.
Outlook is mixed; rare earth demand is rising due to AI and energy transitions, but high concentration and volatility pose risks. Investment opportunity lies in commodity cycle exposure, yet investors face geopolitical and inflation uncertainties. Wall Street sentiment is cautious despite thematic tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
